{"date":"2025-08-20","count":16,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6620-2025-08-20-1809-1lw8gsn","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"18:09:35","subject":"公告本公司限制員工權利新股註銷完成變更登記事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-08-20 18:09，「公告本公司限制員工權利新股註銷完成變更登記事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2025-08-20-1733-zuo1n5","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"17:33:11","subject":"公告本公司註銷庫藏股辦理變更登記完成","clause":"第36款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2025-08-20 17:33，「公告本公司註銷庫藏股辦理變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4178-2025-08-20-1722-18li957","company_id":"4178","company":"永笙-KY","market":"上市","industry":"生技醫療","date":"2025-08-20","time":"17:22:34","subject":"代重要子公司台灣永生公告本公司法人董事改派代表人","clause":"第6款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：永笙-KY（4178），2025-08-20 17:22，「代重要子公司台灣永生公告本公司法人董事改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4139-2025-08-20-1706-11bqfz8","company_id":"4139","company":"馬光-KY","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"17:06:19","subject":"代子公司馬光國際依公開發行公司資金貸與及背書保證處理準則第22條第1項第3款公告","clause":"第23款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：馬光-KY（4139），2025-08-20 17:06，「代子公司馬光國際依公開發行公司資金貸與及背書保證處理準則第22條第1項第3款公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4139-2025-08-20-1705-knofar","company_id":"4139","company":"馬光-KY","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"17:05:55","subject":"公告本公司董事會通過114年第二季合併財務報告案","clause":"第31款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：馬光-KY（4139），2025-08-20 17:05，「公告本公司董事會通過114年第二季合併財務報告案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-08-20-1657-1kbupvl","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-08-20","time":"16:57:07","subject":"公告修正本公司113年度股東會年報部分內容","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-08-20 16:57，「公告修正本公司113年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2025-08-20-1651-1igyjof","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"16:51:22","subject":"公告本公司洽定上櫃買賣開始日並自同日起終止興櫃買賣","clause":"第28款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2025-08-20 16:51，「公告本公司洽定上櫃買賣開始日並自同日起終止興櫃買賣」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6535-2025-08-20-1616-uhe5fz","company_id":"6535","company":"順藥","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"16:16:40","subject":"公告本公司董事會通過113年現金增資資金運用計畫變更","clause":"第16款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：順藥（6535），2025-08-20 16:16，「公告本公司董事會通過113年現金增資資金運用計畫變更」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4737-2025-08-20-1616-h26tg","company_id":"4737","company":"華廣","market":"上市","industry":"生技醫療","date":"2025-08-20","time":"16:16:04","subject":"公告本公司調整股票股利配股率","clause":"第14款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：華廣（4737），2025-08-20 16:16，「公告本公司調整股票股利配股率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-08-20-1558-1hgxw86","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"15:58:47","subject":"公告本公司113年度年報部分內容補正","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-08-20 15:58，「公告本公司113年度年報部分內容補正」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2025-08-20-1545-arkidq","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2025-08-20","time":"15:45:44","subject":"公告本公司114年第一次現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2025-08-20 15:45，「公告本公司114年第一次現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4162-2025-08-20-1524-naxvgk","company_id":"4162","company":"智擎","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"15:24:02","subject":"本公司研發中新藥PEP08，經台灣衛福部食藥署審查，獲准進行第一期人體臨床試驗","clause":"第10款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：智擎（4162），2025-08-20 15:24，「本公司研發中新藥PEP08，經台灣衛福部食藥署審查，獲准進行第一期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4162-2025-08-20-1519-1xvvjr2","company_id":"4162","company":"智擎","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"15:19:59","subject":"公告本公司補正113年度年報之氣候相關資訊執行情形內容","clause":"第50款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：智擎（4162），2025-08-20 15:19，「公告本公司補正113年度年報之氣候相關資訊執行情形內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2025-08-20-1516-141k8w6","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2025-08-20","time":"15:16:43","subject":"公告本公司現金股利配發基準日","clause":"第14款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2025-08-20 15:16，「公告本公司現金股利配發基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6469-2025-08-20-1448-16pn36z","company_id":"6469","company":"大樹","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"14:48:12","subject":"公告補正本公司113年度年報部份內容","clause":"第50款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：大樹（6469），2025-08-20 14:48，「公告補正本公司113年度年報部份內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4161-2025-08-20-1348-1kbupvl","company_id":"4161","company":"聿新科","market":"上櫃","industry":"生技醫療","date":"2025-08-20","time":"13:48:40","subject":"公告修正本公司113年度股東會年報部分內容","clause":"第50款","fact_date":"2025-08-20","cite_as":"公開資訊觀測站重大訊息：聿新科（4161），2025-08-20 13:48，「公告修正本公司113年度股東會年報部分內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}